Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003457 · ClinicalTrials.gov registry record · Phase 2
Antineoplaston Therapy in Treating Patients With Brain Tumors
A Phase 2 study of Refractory Brain Tumors, sponsored by Burzynski Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00003457 is a Phase 2 study of Refractory Brain Tumors that has completed, run by Burzynski Research Institute. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00003457, a Phase 2 study of Refractory Brain Tumors, has completed, sponsored by Burzynski Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Current therapies for adults with persistent or recurrent brain tumors provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of adults with persistent or recurrent brain tumors. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on adults with persistent or recurrent brain tumors.
Conditions Studied
Interventions
- DRUG Antineoplaston therapy (Atengenal + Astugenal)
Study Locations (1)
Texas
- Burzynski Clinic - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1996-07 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003457
The ClinicalTrials.gov registry entry for NCT00003457 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Burzynski Research Institute, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Refractory Brain Tumors appearing as the primary indexed condition, and to 1 intervention - of which Antineoplaston therapy (Atengenal + Astugenal) is the first listed.
NCT00003457 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00003457 about?
NCT00003457 is a clinical study titled "Antineoplaston Therapy in Treating Patients With Brain Tumors". RATIONALE: Current therapies for adults with persistent or recurrent brain tumors provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of adults with persistent or recurrent brain tumors. PURPOSE: Thi...
What is the current status of trial NCT00003457?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1996-07. Estimated completion is 2012-02.
What conditions does trial NCT00003457 study?
This clinical trial studies the following conditions: Refractory Brain Tumors.
What interventions are being tested in trial NCT00003457?
The interventions under investigation include: Antineoplaston therapy (Atengenal + Astugenal) (DRUG).
Who is sponsoring clinical trial NCT00003457?
This trial is sponsored by Burzynski Research Institute, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003457 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.